#News for #Investors and #Media: Gastroesophageal adenocarcinoma (GEA) is one of the most difficult cancers to treat and – as the fifth most common cancer worldwide – continues to be a global health challenge. Today, we announced positive Phase 3 data from a study evaluating a combination regimen including a HER2-targeted bispecific antibody that we have licensed in Asia Pacific (excluding Japan) and chemotherapy with and without our PD-1 inhibitor in patients with HER2+ GEA. These results have the potential to improve outcomes for people with this aggressive and often devastating disease. Learn more about today’s news: https://lnkd.in/g9acB8Kd #BeOneInnovator #Oncology #StomachCancer
BeOne Medicines
Biotechnology Research
Cambridge, Massachusetts 221,690 followers
Cancer has no borders. Neither do we.
About us
BeOne Medicines is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram. We all share the responsibility to report adverse events observed with our products so that they may be investigated, actioned, and communicated accordingly. To report an adverse event or side effect, please talk to your healthcare provider and contact us here: https://beonemedicines.com/contact-us/report-adverse-event/.
- Website
-
https://beonemedicines.com/
External link for BeOne Medicines
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2010
- Specialties
- oncology, hematology, cancer treatment, solid tumor, and targeted therapy
Locations
Employees at BeOne Medicines
-
Andrew Harmon
Clinical recruiter at BeOne Medicines
-
Scott Carter
VP, Associate General Counsel, Business Development at BeOne Medicines
-
Alex Emanuel
Healthcare marketer, commercial operations and analytics professional
-
Elizabeth S.
Project Management Consultant | Pharmaceutical Industry
Updates
-
#TeamBeOne is heading to #ASH2025! ASH abstracts are now live, and while we’re not sharing details on our presence just yet, we’re excited to engage with the hematology community and be part of this year’s scientific program. Over the coming weeks, we’ll be highlighting our contributions and the latest insights from our research. Stay tuned – there’s more to come! #BeOneInnovator
-
There are countless reasons why people take part in Blood Cancer United’s #LightTheNight walks - to support loved ones, stand with those living with blood cancer, or honor the memory of those we’ve lost. At BeOne, colleagues across the U.S. walked with purpose, united by a shared commitment to improving outcomes for patients, caregivers, families, and friends whose lives are touched by blood cancer. Hear their stories and what inspires them to walk. #WhyIWalk #BeOneVoice #TeamBeOne
-
This year, #TeamBeOne across the U.S. supported over 10 regional Blood Cancer Conferences hosted by Blood Cancer United. With more than 4,000 attendees, these gatherings brought together patients, caregivers, and healthcare professionals for a day of education, connection, and hope. As a National Sponsor, we’re proud to support these important conferences and grateful for the opportunity to learn from and connect with the blood cancer community. Thank you to Blood Cancer United for your continued leadership in education, research, and support. #BeOneVoice
-
-
Coughing, shortness of breath, or persistent fatigue aren’t always “just a cold.” They can sometimes be early warning signs of lung cancer – a serious condition that often goes undetected until it’s advanced. Changing this story requires more research, wider access to testing and innovative treatments. At BeOne Medicines, we’re committed to putting #PatientsFirst and working toward a better future for lung cancer patients. This #LungCancerAwarenessMonth, we encourage anyone with concerns not to wait – early detection saves lives. According to the World Health Organization, lung cancer cases are expected to increase dramatically by 2050. By how much? The answer might surprise you! #BeOneAgainstCancer
This content isn’t available here
Access this content and more in the LinkedIn app
-
Quality isn’t optional – it’s for everyone, by everyone This #WorldQualityWeek, we invite you to meet Raheem, Supervisor of our Drug Substance Purification team. In this video, he shares what it means to uphold excellence - from the teamwork that powers every shift to the shared commitment that keeps patients at the heart of everything we do. Learn more about our mission: https://lnkd.in/gK49N_GC #TeamBeOne #PatientsFirst #ThinkDifferently
-
BeOne Medicines reposted this
Looking for a powerful way to spread awareness this #LungCancerAwarenessMonth? Find a Shine A Light on Lung Cancer® event near you! Together, we can spread awareness, inspire hope, and make a difference. 🩵 Be part of the movement: https://lnkd.in/gAb_-V6f
-
-
#News for #Investors and #Media: BeOne Medicines announces third quarter 2025 financial results and business updates. Read the full press release here: https://lnkd.in/eEEAAfWN
-
Meet Adam Roach, Senior Vice President and Head of Japan and Asia Pacific. He shares what gives him a sense of purpose and inspires his work at BeOne every day. Swipe to discover his thoughts on: - What drives his passion for the pharmaceutical industry and its impact on global healthcare - The most important challenge facing his region, and how he addresses it as a leader - How our industry can improve access for underserved populations #TeamBeOne
-
BeOne Medicines reposted this
Ensuring equity and access to innovation in oncology as BeOne Medicines’ SVP, Head of Europe
Despite the significant progress we made, it's clear that patients across Europe still face vastly different timelines to access new oncology treatments. While some countries are fortunate enough to provide access in just over 100 days, others are faced with delays of nearly 1,000 days. These numbers are not just statistics; they represent lives. Each delay means precious time that patients and their families simply don't have, and it's a chance of survival that cannot be regained. At BeOne Medicines, we are deeply committed to changing this reality. By collaborating with healthcare partners, we aim to make faster, fairer access to innovation a reality not only in Europe but globally. #Oncology #BeOneAgainstCancer #Innovation #Access
-